News | July 22, 2014

NorthStar Medical Radioisotopes Breaks Ground for New Facility in Beloit, Wis.

Facility to support company’s work at University of Missouri Research Reactor to develop domestic source of molybdenum-99

July 22, 2014 — NorthStar Medical Radioisotopes broke ground on a new 50,000-square-foot facility in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99).

Mo-99 is the parent isotope of technetium-99m (Tc-99m), the most widely used radioisotope in medical diagnostic imaging. Currently, nearly all Mo-99 is generated using highly enriched uranium (HEU) at aging facilities located outside of the United States, leading to product shortages and creating safety and national security concerns.

NorthStar is pursuing two non-uranium- and non-fission-based production processes that would help establish the first domestic source of Mo-99 since 1990. Both processes generate only a benign waste stream.

The new facility is phase one in the planned development of a 32-acre corporate campus for NorthStar. It will support the company’s work at the University of Missouri Research Reactor in Columbia, Mo., where NorthStar is developing a neutron capture process to generate Mo-99.

The facility will provide ancillary processes, packaging and products, including final assembly and testing of the proprietary RadioGenix intelligent isotope separation system. NorthStar will also move its company headquarters, currently located in Madison, Wis., to the facility.

“This groundbreaking is an exciting milestone for NorthStar Medical Radioisotopes and an important step toward achieving the goal of establishing a reliable and commercially viable domestic source of Mo-99,” said NorthStar President and CEO George P. Messina.

Phase two of the campus development project would see the building expanded; the site could accommodate a building as large as 110,000 square feet. Phase three would include construction of a linear accelerator facility for use in the second Mo-99-generation process that NorthStar is developing. A third building also could be constructed on the site in the future as the company continues to expand.

For more information: www.northstarnm.com

Related Content

News | Radiopharmaceuticals and Tracers

August 2, 2019 — The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) ...

Home August 02, 2019
Home
News | Radiopharmaceuticals and Tracers

July 16, 2019 – NorthStar Medical Radioisotopes LLC announced completion of construction on its 20,000-square-foot ...

Home July 16, 2019
Home
News | Radiopharmaceuticals and Tracers

June 5, 2019 – BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel ...

Home June 05, 2019
Home
News | Radiopharmaceuticals and Tracers

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular ...

Home May 17, 2019
Home
News | Radiopharmaceuticals and Tracers | Jeff Zagoudis, Associate Editor

May 10, 2019 — Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in ...

Home May 10, 2019
Home
News | Radiopharmaceuticals and Tracers

October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide ...

Home October 12, 2018
Home
Feature | Radiopharmaceuticals and Tracers | Dave Fornell

February 8, 2018 — The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) recently took ...

Home February 26, 2018
Home
News | Radiopharmaceuticals and Tracers

August 30, 2017 — ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary ...

Home August 30, 2017
Home
News | Radiopharmaceuticals and Tracers

May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the ...

Home May 22, 2017
Home
News | Radiopharmaceuticals and Tracers

April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the ...

Home April 28, 2017
Home
Subscribe Now